An Observational Study Designed to Elucidate the Pathways by Which Inflammation Contributes to Anaemia in Sick Rural African Children From 6 Months to 36 Months
NCT ID: NCT04095884
Last Updated: 2020-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2019-07-17
2023-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The Investigator will:
1. Recruit 50 sick febrile children in each of 4 categories; Upper Respiratory tract infections, Lower respiratory tract infections (pneumonia), Urinary tract infections, gastroenteritis.
2. Assess iron absorption and its relationship to iron and anaemia status, inflammation, EPO, erythroferrone and hepcidin.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Iron and Infection: Neonatal Nutritional Immunity
NCT03353051
Sub-clinical Inflammation and Iron Supplementation
NCT01198574
Efficacy of Iron Fortified Complementary Food and IPT of Malaria in Young Children in Côte d'Ivoire
NCT01634945
The Role and Effect of Anemia in Children With Pneumonia
NCT02466672
Acute vs. Delayed Iron: Effect on Red Cell Iron Incorporation in Severe Malaria
NCT01754701
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Hypothesis 1: On day 0, 3 and 7 of acute illness, hepcidin will be higher when compared to levels in well children. On Day 14 iron absorption and hepcidin levels will have returned to baseline.
Research Question 1: What affect do non-malarial infections (upper respiratory tract infections, lower respiratory tract infections, urinary tract infections and gastroenteritis) have on hepcidin levels and how long does this effect last?
Aim 2: To retest our existing hepcidin threshold for discriminating iron absorbers from non-absorbers by repeating our prior ROC analysis based on a much larger sample.
Hypothesis: On day 0, 3 and 7 of acute illness, iron absorption will be lower. On Day 14, iron absorption will be equivalent to iron absorption in well children. Note that the Hepcidin levels and iron absorption data obtained in this study will be compared with the results obtained from similarly aged children in IDeA Study 1 (SCC 1664). Also note that The investigator anticipate that most of the children enrolled in this study will have a base-line level of anaemia (eg Hgb\<11g/dL).
Research Question: What is the relationship between hepcidin and oral iron absorption in acute illness and convalescence and how does this differ from the relationship in well children?
Aim 3: To examine EPO synthesis and EPO resistance in children with acute non-malarial infections?
Hypotheses:
1. Children with acute non-malaria infections will have both acute and chronic anaemia of inflammation.
2. EPO is increased during acute infection.
Research Question: Is there decreased EPO synthesis and/or increased EPO resistance in children with acute non-malarial infections living in rural Gambia?
Aim 4: To examine erythroferrone in children with acute non-malarial infections leaving in rural Gambia.
Hypothesis: First The investigator will conduct a hypothesis-free exploratory analysis to assess whether erythroferrone behaves as predicted based upon mouse models (ie up-regulated by stress erythropoiesis and inversely related to hepcidin). The investigator additionally hypothesize that there may be a vicious cycle initiated by inflammation and then perpetuated by the consequent low levels of (iron-restricted) erythropoiesis, leading to low erythroferrone and loss of hepcidin suppression.
Research Question: What is the relationship between erythroferrone, iron status, inflammation, hepcidin, EPO and CRP in anaemic and non-anaemic children living in rural Gambia? This is an observational study of 200 sick children who will be recruited at the Keneba clinic. Each child will be seen four times (at day 0, 3, 7 14).
200 subjects aged 6 -36m brought to Keneba clinic with an acute illness. 50 patients from each category: Upper respiratory tract infections (including ear, nose and throat infections), Lower respiratory tract infections, urinary tract infections and gastroenteritis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Urinary Tract Infection
Inclusion criteria (one from the list below):
1. Positive leukocytes, positive nitrites on dipstick
2. Negative leukocytes, Positive nitrites on dipstick
3. Positive leukocytes, negative nitrites, plus bacteriuria on microscopy
4. Positive leukocytes, negative nitrities plus no bacteriuria, only pyuria on microscopy PLUS clinical features e.g. fever, pain on urination, offensive smelling urine.
Exclusion criteria (one from the list below):
1\. No evidence of UTI on dipstick
blood sampling
observational study and no intervention will be given. only blood samples collected and treated with iron supplements
Upper respiratory tract infection
Inclusion criteria (one from the list below)::
1. Evidence of nasal discharge AND/OR
2. Inflammation throat/ tonsils on direct examination AND/OR
3. Inflammation of middle or outer ear on direct examination
4. History of fever AND history of stridor/ barking cough
5. History of fever AND lymphadenopathy AND/ OR URTI symptoms i.e sore throat/ cough
Exclusion criteria (one from the list below)::
1. Foreign body inserted in either nose/ ear
2. Traumatic perforation of ear drum
3. Allergic rhinitis i.e. good contact history
4. Evidence of LRTI
blood sampling
observational study and no intervention will be given. only blood samples collected and treated with iron supplements
Lower respiratory tract infection
Inclusion criteria (one from the list below):
1. Focal signs on auscultation of the chest i.e crepitations/ wheeze/ reduced air entry
2. Fever \> 38.5C AND chest recessions AND/OR raised respiratory rate
3. Radiological evidence of LRTI
Exclusion criteria (one from the list below):
1\. Positive malaria test OR suspicion of metabolic acidosis causing tachypnoea and fever
blood sampling
observational study and no intervention will be given. only blood samples collected and treated with iron supplements
Diarrhoea/ gastroenteritis
Inclusion criteria (one from the list below):
1. Abrupt onset of 3 or more loose/liquid stools/ day
2. Ova, cysts, parasites identified on stool microscopy PLUS symptomatic diarrhoea,and/ or fever and/or vomiting
3. Fever AND vomiting WITHOUT other source of fever i.e UTI/LRTI/URTI
Exclusion criteria (one from the list below):
1. Normal breast milk stool
2. Neurological cause of vomiting
blood sampling
observational study and no intervention will be given. only blood samples collected and treated with iron supplements
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood sampling
observational study and no intervention will be given. only blood samples collected and treated with iron supplements
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Fever ( \> 37.5C) and/or signs of illness.
* Signed or fingerprinted or personally marked written informed consent obtained from their parent/guardian.
* Parent/guardian plans for subject to reside in study site area and are able and willing to adhere to all protocol visits and procedures.
Exclusion Criteria
2. Sickle cell disease
3. Evidence of hookworm infection by stool microscopy
4. Administration of immunosuppressants or other immune-modifying agents within 90 days prior to study IP administration (e.g., systemic corticosteroids at doses equivalent to ≥ 0.5 mg/kg/day of prednisone for more than 14 days; topical steroids including inhaled and intranasal steroids are not exclusionary).
5. Administration of systemic antibiotic treatment within 3 days prior to study enrolment.
6. Any history of or evidence for chronic clinically significant (as per investigator assessment) disorder or disease (including, but not limited to, immunodeficiency, autoimmunity, malnutrition\*, congenital abnormality, bleeding disorder, and pulmonary, cardiovascular, metabolic, neurologic, renal, or hepatic disease). \* Other than the exclusionary clinical diagnosis of malnutrition for all subjects, in children 2 to 5 years of age, malnutrition is also defined as a weight-for-height Z-score of less than -3 as per WHO reference standards.
7. Any history of human immunodeficiency virus, chronic hepatitis B or chronic hepatitis C infections.
8. Any condition that in the opinion of the investigator might compromise the safety or well-being of the subject or compromise adherence to protocol procedures
9. Participation in another MRC study
6 Months
36 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Oxford
OTHER
London School of Hygiene and Tropical Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Keneba MRC Unit
West Kiang, City of Banjul, The Gambia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SCC 17097
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.